Trial site
Velocity Clinical Research-Huntington Park
- 12running trials
- 13closed trials
The trials here
What the 25 trials at this site are about, from their registry records.
- Conditions
- Obesity14 trials
- Type 2 diabetes10 trials
- Fatty liver disease (MASLD/MASH)4 trials
- Chronic kidney disease1 trial
- Cushing's syndrome1 trial
- High blood pressure1 trial
- Liver cirrhosis1 trial
- Phase
- Phase 212 trials
- Phase 311 trials
- Phase 42 trials
- Status
- Completed12 trials
- Recruiting6 trials
- Active, not recruiting5 trials
- Not yet recruiting1 trial
- Terminated1 trial
- Lead sponsor
- Eli Lilly and Company12 trials
- Boehringer Ingelheim4 trials
- Amgen1 trial
- Cascade Pharmaceuticals, Inc1 trial
- Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)1 trial
- and 6 more
Running trials
Not yet recruiting
Recruiting
Recruiting
Active, not recruiting
Recruiting
Recruiting
Recruiting
Active, not recruiting
Recruiting
Active, not recruiting
Active, not recruiting
Active, not recruiting
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
- Type 2 diabetes4 recruiting
- Obesity3 recruiting
- Fatty liver disease (MASLD/MASH)2 recruiting
- Cushing's syndrome1 recruiting
- High blood pressure1 recruiting
- Liver cirrhosis1 recruiting
Closed trials
Terminated
A Study of LY3549492 in Adults With Obesity or Overweight With Type 2 Diabetes
Completed
Completed
Study of CD388 for the Prevention of Influenza in Subjects Not at Risk for Influenza Complications
Completed
Completed
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age
Completed
A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight
Completed
Completed
A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight
Completed
Completed
A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes
Completed
Completed
A Study to Evaluate a Modified RNA Vaccine Against Influenza in Adults 18 Years of Age or Older
Completed
Site data: ClinicalTrials.govUpdated 17 Nov 2026